The company’s revenue increased by 119.2% from last year to ₹641.5 crore. The figure was lower by 17% when compared to the March quarter.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter stood at ₹222.9 crore from ₹34.5 crore during the same quarter last year, a growth of 546%. Sequentially though, the EBITDA figure was down 27.5%.
EBITDA margin for the quarter expanded to 34.7% from 11.8% last year, but narrowed from the March quarter figure of 39.6%.
Net profit for the quarter grew by nearly 10x to ₹147 crore from ₹14 crore last year. Sequentially, the profitability figure was down 30%.
The lumpy nature of the CDMO business is the reason why numbers appear lower on a sequential basis, although the year-on-year numbers are strong.
Results are also better than Nuvama’s estimates, who had projected the revenue to be ₹571.3 crore, EBITDA to be ₹142.8 crore and a profit outlook of ₹94.1 crore.
Neuland Laboratories’ management said that the growth during this quarter was led by the Custom Manufacturing and Generic Drug segments.
The management also said that the depth of customer conversations today is significantly stronger and are increasingly engaging on broader capacity-led discussions rather than individual projects alone.
All four analysts tracking the stock have a “buy” rating on it. The consensus estimate of price targets implies an upside potential of 18% from current levels. JM Financial has the highest price target on the street for the stock at ₹25,819.
Shares of Neuland Laboratories are trading 6.7% higher on Thursday at ₹21,290. The stock has delivered positive returns for five months in a row now, and is up 31% so far in 2026.
